Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Mitochondrial Biology

Background:

• Platinum(IV) prodrugs offer advantages over platinum(II) drugs like cisplatin.
• The translocator protein (TSPO) is a potential target in cancer therapy.
• Quinazolinecarboxamide ligands can be designed to target TSPO.

Purpose of the Study:

• To design, synthesize, and characterize novel platinum(IV) prodrugs with a TSPO-binding ligand (L3).
• To evaluate the biological activity, including cytotoxicity and cellular mechanisms, of these new compounds.
• To compare their efficacy against breast cancer cells with existing platinum drugs and the free ligand.

Main Methods:

• Synthesis and characterization of platinum(IV) complexes.
• Cytotoxicity assays in MCF-7 breast cancer and MCF-10A cells.
• Cellular uptake, ROS generation, DNA damage, and mitochondrial function studies.
• Molecular docking to investigate ligand-TSPO interactions.

Main Results:

• The platinum(IV) complex C-Pt1 exhibited the highest efficacy.
• C-Pt1 demonstrated a multimodal mechanism of action.
• This mechanism involves DNA damage, significant ROS production, and mitochondrial dysfunction, including loss of membrane potential and morphological changes.

Conclusions:

• The novel platinum(IV) prodrugs, particularly C-Pt1, show promising anti-cancer potential.
• Targeting TSPO with platinum(IV) complexes offers a viable strategy for cancer treatment.
• The multimodal action of C-Pt1 highlights its potential for overcoming drug resistance.